A hypoxia-responsive glial cell-specific gene therapy vector for targeting retinal neovascularization

Area of Science:

• Ophthalmology
• Molecular Biology
• Gene Therapy

Background:

• Müller cells are key glial cells in the retina involved in neovascularization.
• Tissue hypoxia triggers retinal neovascularization, a hallmark of diseases like proliferative diabetic retinopathy.
• Previous work established a hypoxia-responsive, GFAP-promoter-driven vector for Müller cell targeting.

Purpose of the Study:

• To compare the efficacy of regulated and unregulated Müller cell delivery of endostatin in preventing neovascularization.
• To evaluate a novel hypoxia-regulated, glial cell-specific vector system for therapeutic delivery.

Main Methods:

• Endostatin cDNA was cloned into vectors with hypoxia-regulated or unregulated GFAP promoters (scAAV2).
• Mice underwent intravitreal injections of vectors before oxygen-induced retinopathy (OIR) induction.
• Neovascularization, avascular areas, and transgene/VEGF expression were assessed post-treatment.

Main Results:

• The hypoxia-regulated vector reduced neovascularization by 93% and vaso-obliteration by 90%, similar to the unregulated vector.
• Significant reduction in VEGF protein was observed with regulated endostatin vector treatment.
• Endostatin production was undetectable in retinas without vascular damage, indicating hypoxia-dependent regulation.

Conclusions:

• Hypoxia-regulated, glial cell-specific endostatin delivery is effective in reducing retinal neovascularization.
• This vector system holds potential for treating neovascularization in proliferative diabetic retinopathy.